Novack Jeffrey Adam 4
4 · CareDx, Inc. · Filed May 6, 2026
Research Summary
AI-generated summary of this filing
CareDx (CDNA) Secretary Jeffrey Novack Sells Shares
What Happened
Jeffrey Adam Novack, Secretary and General Counsel of CareDx, Inc. (CDNA), sold 2,688 shares on May 5, 2026 in an open‑market or private sale. The Form 4 reports a weighted average sale price of $20.68 per share for total proceeds of $55,581. The sale is reported as a disposition (S) and was effected under a pre‑established trading plan.
Key Details
- Transaction date: May 5, 2026; Form 4 filed May 6, 2026 (timely filing).
- Shares sold: 2,688; weighted average price reported: $20.68; total proceeds: $55,581.
- Price range: trades occurred at prices between $20.405 and $21.26 per share (footnote); the filer can provide a breakdown on request.
- Sale executed pursuant to a Rule 10b5‑1 trading plan adopted September 4, 2025 (pre‑arranged plan).
- Shares owned after the transaction: not specified in the information provided.
Context
The sale was made under a Rule 10b5‑1 plan, which is a pre‑arranged trading program that allows insiders to transact shares at scheduled times and is commonly used to avoid concerns about trading on material nonpublic information. Sales are often routine and do not necessarily indicate a change in view about the company; no inference about the insider’s motives should be drawn from this single filing.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-05-05$20.68/sh−2,688$55,581→ 113,924 total
Footnotes (2)
- [F1]The transaction reported in this row was effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on September 4, 2025.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.405 to $21.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.